Navigation Links
CCPM Issues Statement on FDA's GIVE Initiative
Date:10/4/2007

WASHINGTON, Oct. 5 /PRNewswire-USNewswire/ -- The Coalition for a Competitive Pharmaceutical Market (CCPM) issued the following statement today on the Food and Drug Administration's announcement regarding its "Generic Initiative for Value and Efficiency" (GIVE):

"With consumers, employers, insurers, and policymakers grappling with how to manage escalating prescription drug costs, it is critical that FDA and Congress continue to focus on ways to enhance timely generic access. Today's announcement of the GIVE program by FDA helps focus attention on the need to bolster the generic drug program, but real work remains on important issues that are hindering consumer access. To achieve this, FDA and Congress must address existing issues including the lack of a workable approval pathway for biogenerics, increased funding for the Office of Generic Drugs (OGD) and stopping brand-name pharmaceutical companies from unfairly extending brand drug patents.

"As momentum grows for access to biogenerics, it is imperative that Congress provide FDA with a clear process for facilitating the development and approval of these life-saving medicines that would give patients affordable alternatives to the brand drugs they need. Regulatory and administrative actions are also needed to restructure OGD programs to ensure timely generic access.

"Finally, insufficient OGD funding is slowing the process of getting generic drugs to market. While we welcome FDA's statement that it will hire and train new generic drug reviewers, sufficient funding is needed to make this wish a reality. Substantially increasing resources for OGD is critical to increasing competition in the pharmaceutical market and getting generics into the hands of consumers. We applaud the Senate and House members of the Appropriations Committees for recognizing the importance of sufficient funding and we hope this needed increase is included in the final legislation."

CCPM is an organization of large national employers, health plans, pharmacy benefit managers, chain pharmacies, generic drug manufacturers and others committed to improving consumer access to high quality, affordable generic medicines and promoting a vigorous, competitive prescription drug market.

Contact: Katie Braden Huffard, 202-255-5216


'/>"/>
SOURCE CCPM
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Stabilizing RNA in Fresh and Frozen Tissues for RNA Isolation
2. Genomic DNA Preparation from RNAlater Preserved Tissues
3. Preparation of PCR Quality Template DNA from a Wide Range of Tissues Using InstaGene Matrix
4. Using the VersaFluor Fluorometer to Quantitate GUS Expression in Plant Tissues Bombarded With the Biolistic PDS-1000/He System
5. A Novel Process for Gene Expression Profiling of Rat and Mouse Tissues from Formalin-Fixed Paraffin-Embedded Sections Using Microarrays
6. Genome Wide Profiling of Paired Cancerous and Normal Breast Tissues and Rapid Interpretation of Gene Expression Data
7. Evaluation of RNA isolated from human tissues: quality control for surgical and postmortem samples
8. Genomic Analysis of Formalin-Fixed Paraffin Embedded (FFPE) Tissues through the use of Whole Genome Amplification (WGA)
9. Inline intellectual property raises legal issues
10. SC Johnson issues trademark warning over web offer
11. Company issues warning on outsourced software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... manufacturing company, today announced several positive developments that position the Company for the ... result of the transaction, Craig F. Kinghorn has been appointed Chairman of the ...
(Date:5/25/2016)... ... 2016 , ... Founder of the Fitzmaurice Hand Institute in ... of the hand by the National Board of Physicians and Surgeons, as of ... in his pursuit of providing the most comprehensive, effective treatment for his patients, ...
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven Pharmaceutical Holding Company Ltd. ... the company’s orphan drug designation request covering BHV-4157 for the treatment of Spinocerebellar ... FDA. , Spinocerebellar ataxia is a rare, debilitating neurodegenerative disorder that is ...
(Date:5/23/2016)... ... ... need for blood donations in South Texas and across the nation is growing. , But ... blood donations are on the decline. In fact, donations across the country are at their ... Texas in the last four years alone. , There is no substitute for blood. , ...
Breaking Biology Technology:
(Date:3/21/2016)... -- Unique technology combines v ...   Xura, Inc. (NASDAQ: ... communications services, today announced it is working alongside SpeechPro ... particularly those in the Financial Services Sector, the ability ... a mobile app, alongside, and in combination with, traditional ...
(Date:3/15/2016)... 15, 2016 Yissum Research Development Company ... company of the Hebrew University, announced today the formation ... technology of various human biological indicators. Neteera Technologies has ... from private investors. ... detection of electromagnetic emissions from sweat ducts, enables reliable ...
(Date:3/11/2016)... , March 11, 2016 ... new market research report "Image Recognition Market by Technology ... (Marketing and Advertising), by Deployment Type (On-Premises and Cloud), ... To 2022", published by MarketsandMarkets, the global market is ... to USD 29.98 Billion by 2020, at a CAGR ...
Breaking Biology News(10 mins):